PMID- 30937519
OWN - NLM
STAT- MEDLINE
DCOM- 20200303
LR  - 20200303
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Linking)
VI  - 83
IP  - 6
DP  - 2019 Jun
TI  - Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study.
PG  - 1083-1090
LID - 10.1007/s00280-019-03823-4 [doi]
AB  - PURPOSE: There is no standard treatment strategy for patients with 
      extensive-stage small cell lung cancer (SCLC) who have failed two or more prior 
      chemotherapeutic regimens. In this study, we retrospectively evaluated the 
      efficacy and safety of apatinib in patients with extensive-stage SCLC after 
      failure of more than second-line chemotherapy. METHODS: A study group comprised 
      of 22 patients with extensive-stage SCLC after failure of more than two prior 
      chemotherapeutic regimens was given apatinib orally at an initial dose of 500 mg 
      daily until disease progression or unacceptable toxicity. This study was analyzed 
      according to the National Cancer Institute Common Toxicity Criteria for adverse 
      events (AEs) and Response Evaluation Criteria in Solid Tumors (RECIST) for 
      response assessment. RESULTS: Between August 30, 2015, and May 26, 2017, 22 
      patients were enrolled for evaluating the efficacy and safety of apatinib. Among 
      them, 12/22 (54.5%) underwent dose reduction during treatment. Up to July 31, 
      2018, the median progression-free survival rate was 135.0 days [95% confidence 
      interval (CI) 63.8-206.2]. According to the RECIST criteria, the disease control 
      rate (DCR) was 86.4%, 19/22 [comprised of partial response (PR) 18.2%, 4/22; and 
      stable disease (SD) 68.2%, 15/22 patients]. The most frequent AEs were hand-foot 
      syndrome (45.5%, 10/22), secondary hypertension (45.5%, 10/22) and fatigue 
      (40.9%, 9/22). The primary grade 3 or 4 toxicities were hypertension (22.7%, 
      5/22), hand-foot syndrome (13.6%, 3/22), and proteinuria (9.1%, 2/22). 
      CONCLUSIONS: Apatinib exhibits modest activity and acceptable toxicity for 
      patients with heavily pretreated extensive-stage SCLC.
FAU - Li, Hui
AU  - Li H
AD  - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, 
      China.
FAU - Zeng, Jian
AU  - Zeng J
AD  - Department of Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, 
      310022, China.
FAU - Jin, Xiangyu
AU  - Jin X
AD  - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, 
      China.
FAU - Yu, Xinmin
AU  - Yu X
AD  - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, 
      China.
FAU - Zhou, Guoming
AU  - Zhou G
AD  - Department of Laboratory Medicines, Zhejiang Cancer Hospital, Hangzhou, 310022, 
      China.
FAU - Hong, Wei
AU  - Hong W
AUID- ORCID: 0000-0002-2523-161X
AD  - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, 
      China. hongweizjcc@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190401
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Hand-Foot Syndrome/epidemiology/etiology
MH  - Humans
MH  - Hypertension/chemically induced/epidemiology
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Progression-Free Survival
MH  - Protein Kinase Inhibitors/*administration & dosage/adverse effects
MH  - Proteinuria/chemically induced/epidemiology
MH  - Pyridines/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Small Cell Lung Carcinoma/*drug therapy/pathology
OTO - NOTNLM
OT  - Apatinib
OT  - Chemotherapy refractory
OT  - Efficacy
OT  - Safety
OT  - Small cell lung cancer
EDAT- 2019/04/03 06:00
MHDA- 2020/03/04 06:00
CRDT- 2019/04/03 06:00
PHST- 2019/01/12 00:00 [received]
PHST- 2019/03/19 00:00 [accepted]
PHST- 2019/04/03 06:00 [pubmed]
PHST- 2020/03/04 06:00 [medline]
PHST- 2019/04/03 06:00 [entrez]
AID - 10.1007/s00280-019-03823-4 [pii]
AID - 10.1007/s00280-019-03823-4 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2019 Jun;83(6):1083-1090. doi: 
      10.1007/s00280-019-03823-4. Epub 2019 Apr 1.